

3. A Multicenter, Comparative, Two Arm, Phase 3 Study to determine the safety and efficacy of MS-325-Enhanced MRA for Evaluation of aortoiliac Occlusive Disease in patients with known or suspected Peripheral Vascular Disease or Aortic Aneurysm. **Co-Investigator**. Sponsored by EPIX Medical Inc. 2001.

4. Pharmaco economy multicenter study evaluating cost-efficacy for using Gd-DTPA (Magnevist) in CNS MRI. **Co-Investigator**. Sponsored by Schering AG Colombia SA.

5. Randomized, multi-center open label study of the safety (open-label) and efficacy (open-label & blinded reader) of Magnevist® Injection-enhanced magnetic resonance arteriography (MRA) at two dose levels and 2-dimensional-time-of-flight (2D-TOF) MRA in patients undergoing MRA of the infrarenal aorta and peripheral arteries with intra-arterial digital subtraction arteriography (i.a. DSA) as standard of reference. **International Coordinator**. Sponsored by Berlex Laboratories. 2003 – 2005.

6. Multicenter, open-label study of the safety (open-label) and efficacy (open-label and blinded reader) of a single administration of approximately 0.1 mmol/kg of Magnevist® Injection-enhanced magnetic resonance arteriography (MRA) and 2-dimensional-time-of-flight (2D-TOF) MRA in patients with known or suspected renal artery disease undergoing MRA of the renal arteries with intra-arterial digital subtraction arteriography (i.a. DSA) as the standard of reference. **International Coordinator**. Sponsored by Berlex Laboratories. 2004 – 2005.

7. Multicenter, open-label study of the safety (open-label) and efficacy (open-label and blinded reader) of a single administration of approximately 0.1 mmol/kg of Magnevist® Injection-enhanced magnetic resonance arteriography (MRA) and 2-dimensional-time-of-flight (2D-TOF) MRA in patients with known or suspected disease of the aortic arch and cerebral branches who are undergoing MRA of these vessels with intra-arterial digital subtraction arteriography (i.a. DSA) as the standard of reference. **International Coordinator**. Sponsored by Berlex Laboratories. 2004 – 2005.

8. Multicenter, open-label study of the safety (open-label) and efficacy (open-label and blinded reader) of a single administration of approximately 0.1 mmol/kg of Magnevist® Injection-enhanced magnetic resonance arteriography (MRA) and 2-dimensional-time-of-flight (2D-TOF) MRA in patients with known or suspected disease of the calf and/or pedal arteries undergoing MRA of the calf and pedal arteries with intra-arterial digital subtraction arteriography (i.a. DSA) as the standard of reference. **International Coordinator**. Sponsored by Berlex Laboratories. 2004 – 2005.

9. Multi-center, double-blind, randomized, controlled, parallel group, dose comparison study with corresponding blinded image evaluation following a single intravenous injection of three different doses of gadobutrol 1.0 molar (Gadovist®) in patients with known or highly suspected focal blood brain barrier disturbances and/or abnormal vascularity of the central nervous system. **Co-Author and Global Medical Monitor**. Sponsored by Berlex Laboratories. 2005 – 2007.

11. A multicenter, randomized, double-blind, crossover, phase 3 study to determine the safety and efficacy of gadobutrol 1.0 molar (Gadovist®) in patients referred for contrast-enhanced MRI of the central nervous system (CNS). **Author and Global Clinical Leader.** Sponsored by Bayer HealthCare. 2007-2008

12. A multicenter, open-label, phase 3 study to determine the safety and efficacy of gadobutrol 1.0 molar (Gadovist®) in patients referred for contrast-enhanced MRI of the central nervous system (CNS). **Author and Global Clinical Leader.** Sponsored by Bayer HealthCare. 2007-2008

13. Prospective non-randomized observational (pharmaco epidemiologic) cohort study (open-label, multicenter) to assess the magnitude of potential risk with the administration of Magnevist® Injection in patients with moderate to severe renal impairment for the development of nephrogenic systemic fibrosis (NSF) based on diagnostically specific clinical and histopathologic information. **Principal Investigator.** Sponsored by Bayer HealthCare, 2009- Present

14. An open-label, non-randomized study to evaluate the efficacy and safety of BAY 94-9172 (ZK6013443) positron emission tomography (PET) imaging for detection/exclusion of cerebral β-amyloid when compared to postmortem histopathology. **Principal Investigator.** Sponsored by Bayer HealthCare, 2009- Present.

15. A multicenter, open label, phase 3 study for the evaluation of DOTAREM – enhanced MRA compared to time-of-flight MRA in the diagnosis of carotid and vertebral basilar arterial disease. **Co-Principal Investigator.** Sponsored by Guerbet, 2009- Present

16. A Phase II Non-comparative randomized open-label study of multiple regimens of single-agent XL 184 in subjects with Grade IV Astrocytic Tumors in First or Second relapse. **Co-Investigator.** Sponsored by Exelixis, 2010